Niagen Bioscience vs Zevra Therapeutics
Niagen Bioscience is the larger business, with $129m of revenue in fiscal 2025 against $106m for Zevra Therapeutics (1.2 times as much). Zevra Therapeutics grew faster (350.9% against 29.9%). Zevra Therapeutics kept more of each dollar of sales as profit: a net margin of 78.2% against 13.4%.
| Latest fiscal year | Niagen BioscienceNAGE, 2025 | Zevra TherapeuticsZVRA, 2025 |
|---|---|---|
| Revenue | $129m | $106m |
| Revenue growth | 29.9% | 350.9% |
| Net income | $17.4m | $83.2m |
| Operating margin | — | -59.1% |
| Net margin | 13.4% | 78.2% |
| Return on equity | 28.3% | 85.7% |
| Free cash flow | $13.5m | −$2.4m |
| Cash | $64.8m | $62.4m |
| Total debt | $0 | $63.6m |
| Debt to equity | — | 41.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $251,000 | — |
| Employees | — | 61 |
| Market value | $185m | $604m |
| Price vs our value range | Within our value range | — |
| Moat score | 27 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 2 buys, 0 sales | 0 buys, 13 sales |